Valuation: Cantargia AB

Capitalization 286M 26.79M 25.5M 24.05M 21.24M 37.95M 2.32B 42.11M 106M 970M 100M 98.39M 4.07B P/E ratio 2024 *
-1.65x
P/E ratio 2025 * -1.47x
Enterprise value 54.03M 5.05M 4.81M 4.54M 4.01M 7.16M 438M 7.95M 20.02M 183M 18.95M 18.56M 769M EV / Sales 2024 *
-
EV / Sales 2025 * 1.16x
Free-Float
92.1%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.33%
1 week-5.40%
Current month-16.81%
1 month-7.64%
3 months-18.72%
6 months-56.65%
Current year-7.75%
More quotes
1 week
1.54
Extreme 1.54
1.69
1 month
1.54
Extreme 1.54
1.90
Current year
1.54
Extreme 1.54
1.90
1 year
1.54
Extreme 1.54
5.20
3 years
1.54
Extreme 1.54
19.69
5 years
1.54
Extreme 1.54
71.80
10 years
1.54
Extreme 1.54
71.80
More quotes
Director TitleAgeSince
Chief Executive Officer 63 2025-02-04
Director of Finance/CFO 55 2023-06-14
Chief Tech/Sci/R&D Officer 56 2014-12-31
Manager TitleAgeSince
Chairman 65 2015-12-31
Director/Board Member 54 2017-12-31
Director/Board Member 66 2020-09-30
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.33%-5.40%-54.07%-91.60% 26.79M
-0.77%-2.20%+9.84%+98.50% 118B
-0.10%-5.13%-28.93%+8.03% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+31.02%-22.46% 28.73B
+2.38%+3.29%+58.26%+12.45% 24.63B
+4.61%+2.25%+11.97%-30.27% 23.61B
-2.06%+6.27%+380.22%+952.71% 15.76B
+0.81%-0.80%+189.03%+244.83% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average -0.01%+0.42%+64.57%+128.15% 34.92B
Weighted average by Cap. -0.26%-1.16%+36.47%+99.27%
See all sector performances

Financials

2024 *2025 *
Net sales - 194M 18.13M 17.26M 16.28M 14.38M 25.69M 1.57B 28.51M 71.81M 657M 67.97M 66.6M 2.76B
Net income -166M -15.49M -14.75M -13.91M -12.29M -21.95M -1.34B -24.36M -61.36M -561M -58.07M -56.9M -2.36B -36.09M -3.38M -3.21M -3.03M -2.68M -4.78M -292M -5.31M -13.37M -122M -12.65M -12.4M -513M
Net Debt -232M -21.73M -20.69M -19.51M -17.23M -30.79M -1.88B -34.17M -86.08M -787M -81.47M -79.83M -3.3B -61.76M -5.78M -5.5M -5.19M -4.58M -8.18M -500M -9.08M -22.88M -209M -21.66M -21.22M -878M
More financial data * Estimated data
Logo Cantargia AB
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Employees
21
Calendar
More about the company
Date Price Change Volume
25-02-14 1.559 kr -1.33% 701,828
25-02-13 1.580 kr -1.43% 450,539
25-02-12 1.603 kr +0.63% 486,911
25-02-11 1.593 kr -2.45% 480,938
25-02-10 1.633 kr -0.91% 767,783

Delayed Quote Nasdaq Stockholm, February 14, 2025 at 12:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.559SEK
Average target price
8.333SEK
Spread / Average Target
+434.53%
Consensus

Quarterly revenue - Rate of surprise